ERMA — Enorama Pharma AB Income Statement
0.000.00%
Last trade - 00:00
- SEK107.53m
- SEK103.75m
- SEK1.36m
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | Interim Report | ARS | ARS |
Standards: | SAS | SAS | — | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7.61 | 2.15 | 11 | 6.85 | 1.36 |
Cost of Revenue | |||||
Gross Profit | 10.4 | 2.76 | 3.9 | -0.616 | -3.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 30.5 | 25.2 | 38 | 48.3 | 43.5 |
Operating Profit | -22.9 | -23 | -26.9 | -41.5 | -42.1 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -23.8 | -23.5 | -27.7 | -42 | -44.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -23.8 | -23.5 | -27.7 | -42 | -44.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -23.8 | -23.5 | -27.7 | -42 | -44.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -23.8 | -23.5 | -27.7 | -42 | -44.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.48 | -3.41 | -3.62 | -4.34 | -1.3 |
Dividends per Share |